为探讨经鼻持续气道正压通气(nCPAP)治疗前后阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者血管内皮细胞及纤溶系统的变化及临床意义,选择年龄、性别、体重指数(BMI)无明显差异的OSAHS患者38例和健康者对照组32例,用多导睡眠呼吸监测仪进行监测,以凝固法测定纤维蛋白原(Fg),发色底物法测组织纤溶酶原激活物活性(tPA:A)、纤溶酶原激活物抑制物-1活性(PAI-1:A),酶联免疫法测vonWillebrand因子(vWF)、组织纤溶酶原激活物抗原(tPA:Ag)、纤溶酶原含量(PLg:Ag)和纤溶酶原激活物抑制物-1含量(PAI-1:Ag).结果OSAHS组与对照组比较,vWF、Fg、PAI-1:Ag、PAI-1:A明显升高(P分别＜0.01,0.001,0.001,0.01),PLg:Ag、tPA:A、tPA:Ag、最低血氧饱和度(SaO2low)明显降低(P分别＜0.01,0.001,0.001,0.01).nCPAP治疗后与治疗前比较,vWF、Fg、PAI-1:Ag、PAI-1:A明显降低(P分别＜0.05,0.01,0.01,0.01),PLg:Ag、tPA:A、tPA:Ag、最低SaO2明显升高(P分别＜0.05,0.001,0.001,0.01).提示OSAHS患者血管内皮细胞损伤,凝血功能增强,纤溶系统功能减弱;nCPAP治疗能部分纠正各指标的异常.
作者：杜向阳；张文英；王信杰
来源：山东医药 2003 年 43卷 7期
